Jefferies Sees No Read-Through to The Medicines Company (MDCO) PCSK9 from Alnylam Setback
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
The Medicines Company Provides Progress Update on Ongoing ORION-1 Study of PCSK9si
October 5, 2016 4:35 PM EDTResults from ORION-1 interim analysis with Day 90 follow-up will be presented in Late-Breaking Clinical Trial Session at American Heart Association (AHA) meeting on November 15, 2016
The Company anticipates that top-line data from Day 180 follow-up for up to 200 patients will also be presented at the Late-Breaking Clinical Trial Session
Based on review of safety data by the Independent Data Monitoring Committee through August 26, 2016 (unblinded) and the Company through September 29, 2016 (blinded), no material safety issue and, in particular, no drug-related neuropathy, elevation of liver enzymes or changes in renal function, has been... More
